article thumbnail

A proactive diabetes review model: from concept to nurse-led research

On Medicine

There are a few (but growing) centers that will proactively see patients with diabetes in high-risk areas when admitted to the hospital, however, by far the most common practice is for patients to only be seen by a specialist team, including for diabetes, on receipt of a referral.

Nurses 52
article thumbnail

A unique approach. A unique population. Investing in nurses’ mental health

On Medicine

Nurses play a unique role in our healthcare systems. Nurses in the UK There are approximately 704,520 nurses registered in the UK as of March 2022. It is therefore essential to find ways to support our nurses to allow our healthcare systems to stay alive and thriving.

Nurses 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

The Pharma Data

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

article thumbnail

AI in Healthcare: Care Delivery Use Cases

Perficient: Drug Development

Our recent discussions with Chief Medical Officers, Chief Information Officers, Chief Medical Information Officers, and a VP over Nursing point to this: AI can provide a huge amount of value when it comes to care delivery (e.g., point of care). You may notice that I mentioned AI there and not, more specifically, generative AI.

Nurses 52
article thumbnail

New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19

The Pharma Data

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. who require oxygen therapy due to COVID-19, OR. Yancopoulos , M.D.,

article thumbnail

Children with Arthritis Living in Less Affluent Families More Likely to Report Longer Duration of Morning Joint Stiffness

The Pharma Data

“Time to referral affects how soon we can initiate multidisciplinary care, which may include medications, physical therapy and occupational therapy that are crucial for improving mobility and joint function over these children’s lifetimes.” At its core is Hospital for Special Surgery, nationally ranked No.

Nurses 52
article thumbnail

Kidney cancer charity slams NICE rejection of Keytruda/Inlyta

The Pharma Data

The anti-PD-1 therapy combo was approved in Europe in September 2019 based on findings from the pivotal Phase III KEYNOTE-426 trial, which demonstrated that the drug reduced the risk of death by 47% compared with sunitinib in the indication. Kidney cancer UK has slammed the decision. Source link.

Nurses 52